Feb 17 (Reuters) - Laboratory services provider Labcorp forecast annual profit above Wall Street estimates on Tuesday, ...

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) fell short of the market’s revenue expectations in Q4 CY2025, but ...

Labcorp (NYSE:LH) executives said the company delivered what CEO Adam Schechter called a “very strong year” in 2025, citing ...

Labcorp (LH) stock dips as the company posts mixed Q4 2025 financials, falling short of Street forecasts for revenue while exceeding on earnings. Read more here.

Labcorp posted higher fourth-quarter profit boosted by growth in its diagnostic laboratories business. The company reported net income of $164.7 million, or $1.98 a share, up from $143.4 million, or ...

Guidance for 2026 is for 5.4% midpoint revenue growth and 9% adjusted EPS growth, compared to 2025's 7% revenue and 13% EPS growth. Margin expansion continues, but with slightly moderated growth rates ...

Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors ...

(LH) on Tuesday reported fourth-quarter profit of $164.7 million. The Burlington, North Carolina-based company said it had ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test ...

The earnings results for Labcorp Hldgs (NYSE: LH) for Q4 were made public on Tuesday, February 17, 2026 at 06:50 AM. Here's a ...

LH heads into its Q4 earnings report with rising revenue and EPS expectations, driven by Diagnostics momentum, acquisitions ...